ArticleGynecologic oncology2025
Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectiveNew three-dimensional (3D) augmented reality technology represents an opportunity to improve presurgical planning. This study aimed to measure the accuracy of 3D volumetric rendering on augmented reality headsets to predict extent of disease prior to ovarian cancer cytoreductive surgery.
methodsThis single-institution prospective study took place from 03/01/2024 to 10/01/2024. Utilizing Medivis 3D augmented reality headsets, investigators reviewed volumetric renderings for patients with suspected advanced ovarian cancer prior to scheduled surgery and filled out a survey predicting presence of disease based on anatomic site. Pathology records were later reviewed to confirm the presence of disease. Statistical analyses included Cohen's kappa coefficient, sensitivity/specificity, and positive/negative predictive value measurements.
resultsWe included 15 patients: 9 (60 %) with interval cytoreduction and 6 (40 %) with primary cytoreduction. For procedure, 14 (93 %) had complete gross resection and 1 (7 %) suboptimal cytoreduction (>1 cm of residual disease). Using pathology results as the gold standard for each anatomic site, the 3D headset demonstrated accuracy of 100 % for omentum and pelvic lymph nodes; 93 % for para-aortic lymph nodes, right diaphragm, rectum, and liver; 87 % for small mesentery; and 80 % for small bowel serosa, spleen, and left diaphragm (P > 0.05 for all).
conclusionThe use of preoperative 3D volumetric rendering on augmented reality headsets to predict the extent of ovarian cancer spread showed high agreement with pathology across all anatomic sites studied. Additional research is needed to assess the potential role of this technology in improving surgical planning and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.